Urology eLearning Workshop; A guide to NMIBC - Module 2 Intravesical treatments for NMIBC; History and mode of action

Online Course • medac Pharma

About the CPD course

This is the second module of an eLearning course which features 6 interactive modules; covering a full range of topics within non-muscle invasive bladder cancer. When you finish this module; you should understand; How and why we came to use intravesical therapy for bladder cancer; How the current approach to treatment developed over time; in line with emerging evidence; The rationale behind two key treatments for non-muscle invasive bladder cancer (NMIBC); Mitomycin C (MMC) and bacillus Calmette-Guérin (BCG); The basic mode of action for BCG and MMC.

CPD Provider

medac Pharma

View Profile

Send an enquiry

Full Name*

Email Address*

Contact Number*

Industry*

Your Enquiry*

By submitting this form, you consent to CPD sending you email regarding your application.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

medac Pharma

medac Pharma is a privately owned, pharmaceutical company specialising in the development, diagnosis and treatment of diseases within the key areas of oncology, urology, haematology and autoimmune. The company was originally founded in Germany in 1970 and the UK operation was established in 1993. Since then we have become known for developing innovative products from standard cancer chemotherapy to niche speciality medicines.